Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07338214 | Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations | PHASE1 | COMPLETED | 48 | — | — | Dec 17, 2025 | Mar 31, 2026 | Apr 8, 2026 | 1 | Germany |
Area under the petrelintide plasma concentration time curve from time zero to infinity after a single dose of petrelintide (AUC0-inf)
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength A on Day 1. |
| Arm B | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength B on Day 1. |
| Arm C | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength C on Day 1. |
| Arm D | ACTIVE_COMPARATOR | Each participant will receive a single subcutaneous dose of petrelintide strength D on Day 1. |
| Name | Type | Description |
|---|---|---|
| Petrelintide | DRUG | Solution administered with a syringe |
Inclusion Criteria: * Signed and dated informed consent obtained before any study-related activities. Study-related activities are any procedures that would not have been done during normal management of the participant * BMI: ≥27.0 kg/m2, at screening and Day -1 * Have sufficient venous access to ...